NCT04304248View on ClinicalTrials.gov

Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Albumin-bound paclitaxel, Carboplatin, Toripalimab

Eligible patients will receive Toripalimab 240mg + Albumin-bound paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/-3 days) as neoadjuvant treatment

Trial Locations (1)

Unknown

Sun Yat sen University cancer center, Guangzhou

All Listed Sponsors
lead

Hao Long

OTHER